A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein and Superior Vena Cava Isolation
Eligible age
18–80 yrs
Accepts
All genders
Locations
13 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to assess how safe VARIPULSE catheter system is for treatment of a heart rhythm disease called persistent atrial fibrillation (PsAF) in participants who are having a catheter ablation procedure (treat heart rhythm disease). This includes isolation of pulmonary vein and superior vena cava (heart veins; pulmonary vein isolation \[PVI\] and superior vena cava isolation \[SVCI\]), with or without another technique called posterior wall isolation (PWI). Also, to assess how safe it is for participants who are having a catheter ablation procedure and at the same time receiving another procedure called left atrial appendage occlusion (LAAO; to reduce stroke risk). Additionally, to assess how well VARIPULSE catheter system works over a long period of time for treatment of PsAF in participants undergoing catheter ablation for PVI, SVCI and SVCI+PWI.
Sponsor: Biosense Webster, Inc.
You may qualify if…
- ✓ Participant has been diagnosed with symptomatic persistent atrial fibrillation (PsAF), which is defined as continuous atrial fibrillation (AF) sustained beyond 7 days in duration and less than 365 days in duration, documented by: i. A physician's note documenting diagnosis of symptomatic PsAF, as defined above; and ii. Two electrocardiograms (ECGs) showing continuous AF, with electrocardiogram taken at least 7 days apart (electrocardiograms cannot be greater than (\>) 365 days prior to enrollment); or iii. A 24-hour arrhythmia monitor documenting continuous AF within the last 365 days
- ✓ Participant is aged 18 - 80 years at the time of informed consent
- ✓ Participant is willing and capable of providing informed consent
- ✓ Participant is able and willing to comply with all pre-, post- and follow-up testing and requirement
- ✓ Left atrial appendage occlusion (LAAO) concomitant subset:
- ✓ \- Participant is clinically indicated for a LAAO procedure
You may not qualify if…
- ✕ Participant has continuous AF \> 365 days (longstanding persistent AF)
- ✕ Participant has AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause (for example, untreated documented obstructive sleep apnea, acute alcohol toxicity, etc.)
- ✕ Participant has had previous surgical or catheter ablation for AF
- ✕ Participant is known to require ablation outside the left atrium (LA), superior vena cava (SVC), and the cavotricuspid isthmus (CTI) region (for example, atrioventricular reentrant tachycardia, atrioventricular nodal reentry tachycardia, ventricular tachycardia and Wolff-Parkinson-White)
- ✕ Participant has LA (left atrial) anteroposterior \>= 55 millimeter (mm) (by magnetic resonance imaging \[MRI\], computed tomography \[CT\], or transthoracic echocardiogram \[TTE\]), or if LA diameter is not available, non-index volume \>100 milliliter (mL) confirmed within 365 days prior to enrollment
- ✕ Participant has LA thrombus confirmed by imaging within 48 hours prior to the procedure
- ✕ Participant has severely compromised left ventricular ejection fraction (left ventricle ejection fraction \[LVEF\] less than \[\<\] 40 percent \[%\]) confirmed by imaging performed within 180 days prior to enrollment
- ✕ Participant has uncontrolled heart failure or New York heart association (NYHA) Class III or IV functional classification
Where it's recruiting
Birmingham
Tucson
Jonesboro
Santa Monica
Aurora
Hartford
Atlantis
Edgewood
Traverse City
The Bronx
Oklahoma City
Philadelphia
Source: ClinicalTrials.gov · NCT07527299 · last updated 2026-11-03